CA
TRAX

Clearstead Advisors’s First Tracks Biotherapeutics TRAX Stock Holding History

Clearstead Advisors’s Portfolio TRAX Stock Details TRAX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$61 Buy
+3
New +$56 ﹤0.01% 3449

Other funds holding TRAX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
S
Sanofi Paris, France $534M AUM 205.96% 1-Year Est. Return
FEG
Financial Enhancement Group Anderson, Indiana $839M AUM 18.63% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return
MAP
Moody Aldrich Partners Marblehead, Massachusetts $557M AUM 122.79% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return
TE
Tema ETFs New York $3.09B AUM 72.72% 1-Year Est. Return
YIH
Y-Intercept (HK) Hong Kong $5.05B AUM 17.89% 1-Year Est. Return

Clearstead Advisors's TRAX Position: Q2 2026 in Review

Clearstead Advisors opened a new position in First Tracks Biotherapeutics (TRAX) in Q2 2026: 3 shares worth $61. The stake represents ﹤0.01% of the portfolio and ranks #3449 among its holdings.

38 funds tracked by Wall St. Rank hold TRAX as of Q2 2026.

  • Clearstead Advisors held 3 shares of First Tracks Biotherapeutics worth $61 as of Q2 2026.
  • First Tracks Biotherapeutics was a new Clearstead Advisors position in Q2 2026.
  • First Tracks Biotherapeutics made up ﹤0.01% of Clearstead Advisors's portfolio in Q2 2026, its #3449 holding.
  • 38 funds tracked by Wall St. Rank held First Tracks Biotherapeutics as of Q2 2026.

Based on Clearstead Advisors's 13F filing for Q2 2026, filed 6 Aug 2026.